Testing effectiveness (Phase 2)UnknownNCT00003827What this trial is testingCombination Chemotherapy in Treating Patients With Myelodysplastic SyndromeWho this might be right forLeukemiaMyelodysplastic Syndromes ALZA 25
Not applicableUnknownNCT00295997What this trial is testingDonor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic AnemiaWho this might be right forChronic Myeloproliferative DisordersKidney CancerLeukemia+4 more University of California, San Francisco 35
Testing effectiveness (Phase 2)Active Not RecruitingNCT01522976What this trial is testingAzacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic LeukemiaWho this might be right forChronic Myelomonocytic LeukemiaChronic Myelomonocytic Leukemia-1Chronic Myelomonocytic Leukemia-2+4 more National Cancer Institute (NCI) 282
Early research (Phase 1)Study completedNCT00005946What this trial is testingChemotherapy Plus Donor White Blood Cell Infusion in Treating Patients With Relapsed Hematologic Cancer Following Donor Peripheral Stem Cell TransplantationWho this might be right forLeukemiaLymphomaMultiple Myeloma and Plasma Cell Neoplasm+1 more University of Maryland, Baltimore
Early research (Phase 1)Study completedNCT01139151What this trial is testing4'-Thio-araC (Thiarabine) in Advanced Hematologic MalignanciesWho this might be right forLeukemia M.D. Anderson Cancer Center 31
Early research (Phase 1)Study completedNCT00891137What this trial is testingSafety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic MalignancyWho this might be right forLeukemiaLymphomaMultiple Myeloma+2 more Cellerant Therapeutics 30
Early research (Phase 1)Study completedNCT00569283What this trial is testingDonor Natural Killer Cell Infusion in Preventing Relapse or Graft Failure in Patients Who Have Undergone Donor Bone Marrow TransplantWho this might be right forCancer Asan Medical Center 18
Testing effectiveness (Phase 2)Study completedNCT00352001What this trial is testingLenalidomide and Azacitidine in Treating Patients With Advanced Myelodysplastic SyndromesWho this might be right forLeukemiaMyelodysplastic Syndromes Mikkael Sekeres MD 37
Early research (Phase 1)Ended earlyNCT00234000What this trial is testingAzacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic SyndromesWho this might be right forLeukemiaMyelodysplastic Syndromes Jonsson Comprehensive Cancer Center 1
Testing effectiveness (Phase 2)Study completedNCT00796068What this trial is testingTreosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood TransplantWho this might be right forAcute Biphenotypic LeukemiaAcute Lymphoblastic Leukemia in RemissionAcute Myeloid Leukemia in Remission+4 more Fred Hutchinson Cancer Center 130
Early research (Phase 1)UnknownNCT00769613What this trial is testingEmergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus InfectionsWho this might be right forCancer Milton S. Hershey Medical Center 20
Early research (Phase 1)Study completedNCT00015925What this trial is testingMS-275 in Treating Patients With Hematologic CancerWho this might be right forLeukemiaMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic Syndromes+1 more Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Testing effectiveness (Phase 2)Study completedNCT01839916What this trial is testingDonor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic MalignanciesWho this might be right forAccelerated Phase Chronic Myelogenous LeukemiaAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)+61 more University of Chicago 77
Testing effectiveness (Phase 2)Active Not RecruitingNCT04284787What this trial is testingBLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid LeukemiaWho this might be right forAcute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAcute Myeloid Leukemia Post Cytotoxic Therapy+1 more National Cancer Institute (NCI)
Large-scale testing (Phase 3)Ended earlyNCT00089141What this trial is testingMycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD)Who this might be right forCancer Martin, Paul 151
Early research (Phase 1)Study completedNCT00004871What this trial is testingAzacitidine Plus Phenylbutyrate in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromeWho this might be right forLeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Diseases Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Early research (Phase 1)Study completedNCT00006239What this trial is testingPhenylbutyrate and Tretinoin in Treating Patients With Hematologic CancerWho this might be right forLeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Diseases Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Testing effectiveness (Phase 2)Looking for participantsNCT07096297What this trial is testingLuspatercept + Darbepoetin in MDSWho this might be right forMDS (Myelodysplastic Syndrome) Yale University 60
Testing effectiveness (Phase 2)WithdrawnNCT00816413What this trial is testingDonor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological CancerWho this might be right forChronic Myeloproliferative DisordersLeukemiaLymphoma+2 more University of Nebraska
Large-scale testing (Phase 3)Ended earlyNCT03263091What this trial is testingEfficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion BurdenWho this might be right forPrimary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts)Anemia Kyntra Bio 184